

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
27 October 2005 (27.10.2005)

PCT

(10) International Publication Number
WO 2005/100324 A1

(51) International Patent Classification⁷: **C07D 241/04**,
C07C 217/48, A61K 31/495, 31/137, A61P 25/00, 9/00,
1/00

(21) International Application Number:
PCT/SE2005/000499

(22) International Filing Date: 6 April 2005 (06.04.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0400968-4 14 April 2004 (14.04.2004) SE

(71) Applicant (for all designated States except US): **AS-TRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **DANTZMAN, Cathy**
[US/US]; AstraZeneca Wilmington, P.O. Box 15437,
Wilmington, DE 19850-5437 (US).

(74) Agent: **ASTRAZENECA**; Global Intellectual Property,
S-151 85 Södertälje (SE).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 2- (ARYLALKOXY) -1- PHENYLETHYLAMINE DERIVATIVES AS NK1 ANTAGONIST AND SEROTONIN RE- UPTAKE INHIBITORS



pression and other disorders.

(57) Abstract: Compounds of the following formula (I) wherein R¹ R², n, Ar¹ and A² are as defined in the specification, in vivo-hydrolysable precursors thereof, pharmaceutically acceptable salts thereof, the use in therapy and pharmaceutical compositions and methods of treatment using the same. The example compounds are 1-(2-(naphthylmethoxy)-1-phenylethyl)piperazine derivatives. The compounds are neurokinin 1 (NK₁) receptor antagonist and/or serotonin reuptake inhibitors, with medical indications for de-



WO 2005/100324 A1